Cite
HARVARD Citation
Anolli, M. et al. (n.d.). Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di). Digestive and liver disease. pp. S7-. [Online].